Orexin: The Wakefulness Peptide That Also Burns Calories

What the researchers found

Orexin/hypocretin neuropeptides — produced by a small group of neurons in the hypothalamus — play a significant role in energy expenditure beyond their well-known function in promoting wakefulness. The review finds that orexin-A (hypocretin-1) has a more potent stimulatory effect on energy expenditure than orexin-B (hypocretin-2).

Orexin-A increases whole-body energy expenditure through three main mechanisms: stimulating physical activity, activating the sympathetic nervous system (which increases heart rate and thermogenesis), and directly boosting metabolic rate. The orexin-1 receptor appears to predominantly mediate behaviors that influence energy expenditure.

The two orexin receptors (OX1R and OX2R) appear to have both shared and distinct physiological roles, but the orexin-2 receptor's specific contributions remain poorly characterized.

Why it matters

Orexin is best known as the 'wakefulness peptide' — its absence causes narcolepsy. But this review reveals an equally important role: regulating how many calories you burn. By increasing physical activity, sympathetic tone, and metabolic rate, orexin may be a key factor in why some people are naturally more active and burn more energy. Understanding this could lead to new approaches for treating obesity that target energy expenditure rather than appetite suppression.

The numbers in context

2 orexin peptides (A and B) · 2 receptors (OX1R and OX2R) · Orexin-A: stronger effect on energy expenditure · OX1R: primary mediator of activity-related energy expenditure

How the study worked

Narrative review synthesizing published research on orexin/hypocretin's role in energy expenditure, including studies of physical activity, sympathetic nervous system activation, and whole-body metabolic rate in animal models.

Who was studied

Review article — synthesizes preclinical research primarily from animal models on orexin's role in energy metabolism

What this study cannot tell us

Most evidence comes from animal studies (primarily rodent models). The review acknowledges that orexin-2 receptor function in energy expenditure is poorly understood. Translating these findings to human obesity treatment remains speculative. The review does not include human clinical trial data for orexin-based energy expenditure interventions.

How to read the evidence

This is a narrative review synthesizing primarily animal model research on orexin and energy expenditure. The evidence base is solid for preclinical findings but lacks human clinical data, placing overall evidence at a moderate level.

When this study was published

Published in 2010, this review captures early understanding of orexin's metabolic roles. The field has advanced since, with orexin receptor antagonists now FDA-approved for insomnia, but orexin agonists for energy expenditure remain in preclinical stages.

The bigger picture

Most obesity drugs (like GLP-1 agonists) work by reducing appetite. Orexin offers a fundamentally different approach — increasing the calorie-burning side of the energy equation. With orexin receptor antagonists already FDA-approved for insomnia (suvorexant, lemborexant), there's growing interest in whether orexin agonists could be developed for obesity, though this remains early-stage research.

Questions still open

• Could orexin agonists be developed as obesity treatments that increase energy expenditure rather than suppress appetite?
• Do people with naturally higher orexin levels tend to be more physically active and leaner?
• What are the cardiovascular risks of pharmacologically increasing orexin-mediated sympathetic activation?

Common questions

Read the original research

Hypocretin/orexin and energy expenditure.

Acta physiologica (Oxford, England), 198(3), 303-12

Citation

Teske, J A; Billington, C J; Kotz, C M. (2010). Hypocretin/orexin and energy expenditure.. Acta physiologica (Oxford, England), 198(3), 303-12. https://doi.org/10.1111/j.1748-1716.2010.02075.x